MAPT and Alzheimer disease: We first characterised tau transgenic L1 mice with the NMRI wild-type background and then investigated the effects of HMTM, alone and combined with rivastigmine, for two interconnected metabolic pathways that are critical for the brain energy demands that are known to be impaired in AD: l-lactate metabolism/astrocyte-neuron lactate-shuttle and mitochondrial function.